Company Encyclopedia
View More
name
First Trust Nasdaq Food & Pharma
FTXH.US
News
View More

Pharmaceutical Stocks To Add to Your Watchlist - December 20th

MarketBeat's stock screener tool highlights seven pharmaceutical stocks to watch: Eli Lilly, Alnylam Pharmaceuticals, AbbVie, Insmed, Gilead Sciences, Vertex Pharmaceuticals, and Pfizer. These stocks are noted for their potential growth driven by successful drug pipelines, despite risks like regulatory challenges and patent expiries. The companies have recently seen high trading volumes, indicating investor interest. Each company is involved in developing and commercializing various pharmaceuticals and therapies.

Market Beat·
US
LLY
+1.38%
US
GILD
+2.32%
Market Beat·
US
LLY
+1.38%
US
GILD
+2.32%

U.S. Capital Wealth Advisors LLC Decreases Stock Holdings in AbbVie Inc. $ABBV

U.S. Capital Wealth Advisors LLC reduced its stake in AbbVie Inc. by 30.9% in Q3, owning 47,638 shares worth $11,030,000. AbbVie's stock opened at $227.44, with a 52-week range of $164.39-$244.81. Analysts predict growth, with price targets raised by Morgan Stanley, JPMorgan, HSBC, and Berenberg Bank. AbbVie increased its dividend to $1.73 per share, yielding 3.0%. The company reported Q3 earnings of $1.86 per share, beating estimates.

Market Beat·
US
ABBV
+1.80%
Market Beat·
US
ABBV
+1.80%

MFG Wealth Management Inc. Acquires Shares of 6,431 AbbVie Inc. $ABBV

MFG Wealth Management Inc. acquired 6,431 shares of AbbVie Inc. (NYSE:ABBV) in the third quarter, valued at approximately $1,489,000. AbbVie reported Q3 earnings of $1.86 per share, beating estimates, with revenue of $15.78 billion. The company increased its quarterly dividend to $1.73 per share. Analysts have given AbbVie a consensus rating of 'Moderate Buy' with an average target price of $245.84.

Market Beat·
US
ABBV
+1.80%
Market Beat·
US
ABBV
+1.80%

Ipswich Investment Management Co. Inc. Has $5.34 Million Stock Holdings in Eli Lilly and Company $LLY

Ipswich Investment Management Co. Inc. increased its stake in Eli Lilly and Company by 21.3% in the third quarter, owning 6,995 shares valued at $5.34 million. This makes Eli Lilly 1.2% of Ipswich's holdings. Other institutional investors, like Vanguard and Norges Bank, also adjusted their stakes. Eli Lilly's stock has a consensus 'Moderate Buy' rating with an average target price of $1,141.73. The company reported strong quarterly earnings, with revenue up 53.9% year-over-year.

Market Beat·
US
LLY
+1.38%
Market Beat·
US
LLY
+1.38%

Dynamic Advisor Solutions LLC Purchases 4,692 Shares of Eli Lilly and Company $LLY

Dynamic Advisor Solutions LLC increased its stake in Eli Lilly by 54.8% in Q3, owning 13,261 shares worth $10.1 million. Other firms also adjusted their positions. Analysts have issued positive ratings, with a consensus of 'Moderate Buy' and a price target of $1,141.73. Eli Lilly's oral GLP-1 pill orforglipron showed positive trial results, boosting prospects for FDA approval and commercial adoption.

Market Beat·
US
LLY
+1.38%
Market Beat·
US
LLY
+1.38%
© 2025 Longbridge｜Disclaimer